Omnia Molecular Ltd.

RIGHT DRUGS FIRST

Antibiotics and antifungals rank among the main scientific advances for humankind. Millions of patients have survived life-threatening diseases thanks to penicillin and the rest of antibiotics that followed that magic molecule. Nevertheless, discovery of new anti-infective drugs has slowed down to a minimum. Antibiotic resistance, cost of development, and the lack of new chemical entities all result in the reduction of our therapeutic arsenal against infectious agents.

Omnia Molecular is contributing to the reversal of that trend. Our goal is the development of new families of anti-infectives that combine potency, widespread spectrum, and an ability to overcome the emergence of resistance. As the threat of multi-resistant infections continues to grow the development of our technology becomes ever more relevant. Thank you for your interest in our project.




Omnia News!

:: Omnia presents its project at the Bio-Europe Spring 2008, Madrid [+]



:: Omnia starts its lab operations at Bioincubator PCB-Santander [+]

Contact Omnia



c/Baldiri i Reixac, 15-21 Hèlix building, Bioincubator PCB-Santander
08028 Barcelona Tel. +34 934 020 158
   info@omniamol.com  -  legal warning